Insecticides (india)
Q2 revenue rose 8% to ₹686 Cr, but H1 fell 2%, volumes dropped 6-7% and Q2 PAT was ₹56 Cr. Management is upbeat yet hedges on margins, volume recovery and launch timelines.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Insecticides (india) earnings call we streamed: the live audio and our summary of what management said.
Q2 revenue rose 8% to ₹686 Cr, but H1 fell 2%, volumes dropped 6-7% and Q2 PAT was ₹56 Cr. Management is upbeat yet hedges on margins, volume recovery and launch timelines.
Q2 revenue rose 8% to ₹686 Cr, but H1 fell 2%, volumes dropped 6-7% and Q2 PAT was ₹56 Cr. Management is upbeat yet hedges on margins, volume recovery and launch timelines.
Kairos brand turnover target ₹125 Cr this fiscal. Sotanala formulation start targeted April; may slip 1-2 months.
Q1FY27 was impacted by delayed monsoons, shifting demand later. Despite revenue decline, gross margins improved due to premiumization and inventory management, though EBITDA softened on negative operating leverage.
IIL delivered FY26 revenue of ₹2,140cr (up 7%) with EBITDA of ₹227cr. Strategy focuses on premiumization via the Kaeros brand and R&D partnerships with Nissan and Corteva.
Insecticides India delivered steady 7% revenue growth in FY26, balancing raw material inflation through premiumization and strategic partnerships while preparing for a major brand expansion via its new subsidiary, Kairos.
Insecticides (India) reported FY26 turnover of ₹2,140 Cr. Company shifting toward premiumization with B2C premium product share rising from 51% (FY23) to 58% (FY26).
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.